HC Wainwright Forecasts Alumis’ Q1 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – HC Wainwright increased their Q1 2025 earnings per share estimates for shares of Alumis in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.07) per share for the quarter, up from their prior estimate of ($1.29). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.39) EPS.

ALMS has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Oppenheimer started coverage on shares of Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target for the company. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $26.00.

Alumis Price Performance

NASDAQ ALMS opened at $5.64 on Friday. Alumis has a fifty-two week low of $3.18 and a fifty-two week high of $13.53. The business has a fifty day moving average of $5.39 and a 200-day moving average of $8.34.

Institutional Trading of Alumis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new position in shares of Alumis during the 3rd quarter worth about $27,000. Wells Fargo & Company MN increased its position in Alumis by 77.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after purchasing an additional 3,823 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Alumis during the fourth quarter worth approximately $79,000. MetLife Investment Management LLC acquired a new position in shares of Alumis in the 3rd quarter valued at $89,000. Finally, Marshall Wace LLP purchased a new stake in shares of Alumis during the 4th quarter valued at $108,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.